The nonlinear relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease

被引:3
|
作者
Hu, Yingying [1 ,2 ]
Zhou, Fan [3 ,4 ]
Lei, Fang [2 ,5 ]
Lin, Lijin [1 ,2 ]
Huang, Xuewei [6 ]
Sun, Tao [1 ,2 ]
Liu, Weifang [1 ,2 ]
Zhang, Xingyuan [2 ,5 ]
Cai, Jingjing [2 ,6 ]
She, Zhi-Gang [1 ,2 ]
Li, Hongliang [1 ,2 ]
机构
[1] Wuhan Univ, Renmin Hosp, Dept Cardiol, Wuhan, Peoples R China
[2] Wuhan Univ, Inst Model Anim, Wuhan, Peoples R China
[3] Yangtze Univ, Huanggang Cent Hosp, Dept Gastroenterol, Huanggang, Peoples R China
[4] Huanggang Inst Translat Med, Huanggang, Peoples R China
[5] Wuhan Univ, Sch Basic Med Sci, Wuhan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Cardiol, Changsha, Peoples R China
来源
基金
美国国家科学基金会;
关键词
metabolic dysfunction-associated fatty liver disease; thyroid function parameters; nonlinear relationship; restricted cubic spline analysis; multivariable-adjusted logistic regression models; STIMULATES LEPTIN SECRETION; FREE TRIIODOTHYRONINE; ADIPOSE-TISSUE; HORMONE; RISK; NAFLD; HYPOTHYROIDISM; PATHOGENESIS; THYROTROPIN; PREVALENCE;
D O I
10.3389/fendo.2023.1115354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundThe relationship between thyroid function parameters and metabolic dysfunction-associated fatty liver disease (MAFLD) remains controversial. Additionally, little is known about the relationship between thyroid function parameters and MAFLD in the Chinese population. MethodsWe conducted a retrospective cross-sectional study involving 177,540 individuals with thyroid function tests and MAFLD diagnosis from 2010-2018. The association between thyroid function parameters and MAFLD was evaluated on a continuous scale with restricted cubic spline (RCS) models and by the prior-defined centile categories with multivariable-adjusted logistic regression models. Thyroid function parameters included free triiodothyronine (FT3), free tetra-iodothyronine (FT4), and thyroid stimulating hormone (TSH). Additionally, fully adjusted RCS models stratified by sex, age, and location were studied. ResultsIn the RCS models, the risk of MAFLD increased with higher levels of FT3 when FT3 <5.58pmol/L, while the risk of MAFLD decreased with higher levels of FT3 when FT3 >= 5.58pmol/L (P nonlinearity <0.05). While RCS analysis suggested that the FT4 levels had a negative association with MAFLD (P nonlinearity <0.05), indicating an increase in FT4 levels was associated with a decreased risk of MAFLD. RCS analysis suggested an overall positive association between the concentration of TSH and MAFLD risk (P nonlinearity <0.05). The rising slope was sharper when the TSH concentration was less than 1.79uIU/mL, which indicated the association between TSH and MAFLD risk was tightly interrelated within this range. The multivariable logistic regression showed that populations in the 81st-95th centile had the highest risk of MAFLD among all centiles of FT3/TSH, with the 1st-5th centile as the reference category. ConclusionsOur study suggested nonlinear relationships between thyroid function parameters and MAFLD. Thyroid function parameters could be additional modifiable risk factors apart from the proven risk factors to steer new avenues regarding MAFLD prevention and treatment.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] LIVER FIBROSIS IN ASIANS WITH METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE
    Kim, Byung Ik
    Sohn, Won
    Kwon, Heon-Ju
    Cho, Yong Kyun
    HEPATOLOGY, 2021, 74 : 1022A - 1022A
  • [22] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi Yiwen
    Fan Jiangao
    中华医学杂志(英文版), 2022, (09) : 1009 - 1018
  • [23] Therapeutic developments in metabolic dysfunction-associated fatty liver disease
    Shi, Yiwen
    Fan, Jiangao
    CHINESE MEDICAL JOURNAL, 2022, 135 (09) : 1009 - 1018
  • [24] Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?
    Feng, Gong
    Byrne, Christopher D.
    Targher, Giovanni
    Wang, Fudi
    Zheng, Ming-Hua
    LIVER INTERNATIONAL, 2022, 42 (07) : 1496 - 1502
  • [25] Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
    Bhopale, Kamlesh K.
    Srinivasan, Mukund P.
    LIVERS, 2023, 3 (04): : 597 - 617
  • [26] Metabolic dysfunction-associated fatty liver disease: a year in review
    Alharthi, Jawaher
    Gastaldelli, Amalia
    Cua, Ian Homer
    Ghazinian, Hasmik
    Eslam, Mohammed
    CURRENT OPINION IN GASTROENTEROLOGY, 2022, 38 (03) : 251 - 260
  • [27] The evil relationship between liver fibrosis and cardiovascular disease in metabolic dysfunction-associated fatty liver disease (MAFLD): Looking for the culprit
    Fabris, L.
    Campello, E.
    Cadamuro, M.
    Simioni, P.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2024, 1870 (03):
  • [28] Cardiometabolic characterization in metabolic dysfunction-associated fatty liver disease
    Perdomo, Carolina M.
    Nunez-Cordoba, Jorge M.
    Ezponda, Ana
    Mendoza, Francisco J.
    Ampuero, Javier
    Bastarrika, Gorka
    Fruhbeck, Gema
    Escalada, Javier
    FRONTIERS IN MEDICINE, 2022, 9
  • [29] Epidemiology and diagnosis of metabolic dysfunction-associated fatty liver disease
    Fouad, Yasser
    Alboraie, Mohamed
    Shiha, Gamal
    HEPATOLOGY INTERNATIONAL, 2024, : 827 - 833
  • [30] The Efficacy of Tofogliflozin on Metabolic Dysfunction-Associated Fatty Liver Disease
    Goya, Takeshi
    Imoto, Koji
    Tashiro, Shigeki
    Aoyagi, Tomomi
    Takahashi, Motoi
    Kurokawa, Miho
    Suzuki, Hideo
    Tanaka, Masatake
    Kato, Masaki
    Kohjima, Motoyuki
    Ogawa, Yoshihiro
    GASTROENTEROLOGY INSIGHTS, 2022, 13 (01) : 20 - 26